ASCO® Annual Meeting 2024

Transforming Precision Medicine: AI and Molecular Insights Intersect Across the Cancer Care Continuum

Discover the rapid evolution of precision oncology with our cutting-edge AI technology and expanded molecular portfolio, now including MRD and monitoring, to enhance the delivery of comprehensive insights to providers and biopharma professionals.

*Not an official event of the 2024 ASCO® Annual Meeting. Not sponsored, endorsed, or accredited by ASCO®, Association for Clinical Oncology, or Conquer Cancer®, the ASCO Foundation. Not CME-accredited.

Longitudinal clinical performance of a novel tumor-naive minimal residual disease assay in resected stage II and III colorectal cancer patients: A subset analysis from the GALAXY study in CIRCULATE-Japan poster presentation

The Tempus xM assay, a tumor-naive minimal residual disease (MRD) test, was evaluated for its ability to predict recurrence in stage II and III colorectal cancer patients post-surgery. The study analyzed ctDNA at the landmark time point (4 weeks) and longitudinally. Initial results showed landmark clinical sensitivity and specificity to be 61.1% and 87.9% respectively, and longitudinal sensitivity of 83.3% and specificity of 89.5%. The xM MRD status correlated strongly with disease-free survival, outperforming carcinoembryonic antigen (CEA) levels (HR 9.69 vs 2.13). Finally, for patients who did not receive adjuvant chemotherapy, xM was able to identify those who were likely to relapse an average of 5.62 months before detection on radiographic scans.

Relationship between dynamic changes in circulating tumor fraction and real-world imaging with real-world survival in patients with solid tumors treated with immunotherapy

The research team sought to assess if the addition of molecular response information from the Tempus xM for therapy response monitoring (TRM) assay to real world imaging would allow for more accurate predictions of real world overall survival (rwOS) for patients undergoing treatment on immune checkpoint inhibitors (ICIs). By evaluating patients from Tempus’ real-world multimodal database, the team found that the combination of xM for TRM and traditional imaging approaches provided a more accurate prognostic marker for rwOS than evaluation of imaging alone, with molecular responders having a favorable median rwOS compared to non-responders (16 vs 10 months).

TriHealth Cancer Institute’s collaboration with the Tempus AI TIME program impact on clinical trial operations and enrollment

TriHealth Cancer Institute's integration with Tempus TIME, utilizing AI-powered trial matching software (T-App), has significantly improved clinical trial operations and patient enrollment. Over a 15-month period, the T-App conducted over 8.6 million searches, leading to 2,032 potential matches and 28 patient consents across 45 trials. TIME trials saw a 2.3-fold increase in activations, an 80% reduction in activation time, and a 9.3-fold increase in enrollment compared to non-TIME studies. This partnership demonstrates the effectiveness of AI-enabled screening and structured trial processes in a community health system setting.

Comparison of tumor immune microenvironments (TIMEs) between primary and metastatic sites (Mets) in triple negative breast cancer (TNBC)

This study compared the tumor immune microenvironments (TIMEs) of primary and metastatic triple-negative breast cancer (TNBC) sites, in order to better understand potential impacts to the efficacy of immune checkpoint inhibitor (ICI) therapies. The analysis revealed significant differences in immune cell infiltrates between liver, bone, and primary breast sites, suggesting variations in immunogenicity. The study also highlighted the need for further research on how TIMEs and race may influence ICI treatment outcomes in TNBC.

Comparing the somatic, germline, and immune landscapes of upper tract urothelial carcinoma (UTUC) and UC of the bladder (UCB)

Matched tissue and circulating tumor DNA (ctDNA) analysis in renal cell carcinoma (RCC): Results from a multimodal real-world database

This study found that combining ctDNA and tissue NGS enhances mutation detection in renal cell carcinoma (RCC) patients. The study analyzed de-identified NGS data from the Tempus multimodal database, focusing on patients with matched tissue and ctDNA samples (n=393). Findings indicate higher mutation detection rates and higher concordance in metastatic RCC, suggesting that ctDNA profiling can complement tissue NGS.

Cost-effectiveness of a circulating tumor fraction molecular biomarker for treatment response monitoring

The research team leveraged Tempus’ multimodal real-world database to demonstrate that the xM for therapy response monitoring (TRM) assay has the potential to act as a cost-saving alternative to diagnostic imaging for monitoring treatment response in cancer patients. A patient-level Markov simulation showed that over the course of a planned 24 week treatment, xM for TRM-guided treatment decisions would have reduced the cost of therapy by $4,400 per patient by reducing the duration of inappropriate therapy by 4.3 weeks, where inappropriate therapy is defined as a treatment decision inconsistent with xM for TRM non-responder/responder results. Sensitivity analyses highlighted that an xM for TRM-informed approach is likely to be cost-effective for a wide range of scenarios.

Prognostic value of PORTEC-3 molecular markers by disease risk in a real-world early endometrial cancer cohort

Tempus and AstraZeneca conducted a retrospective study to assess the prognostic value of molecular markers in 740 early-stage endometrial cancer patients across different risk levels. The study stratified patients into high, intermediate, and low risk, analyzing 18-month recurrence-free survival (RFS) based on PORTEC-3 molecular subtypes. Results showed consistent prognostic rankings across all risk levels, indicating these markers may be useful in considering treatment decisions for early-stage endometrial cancer.

Characterization of DNA damage repair (DDR) alterations and the tumor immune microenvironment (TIME) in advanced non-small cell lung cancer (NSCLC)

Clinicopathologic and molecular landscape of invasive mucinous adenocarcinoma of the lung

EVEREST-1: A seamless phase 1/2 study of A2B530, a CEA logic-gated Tmod CAR T-cell therapy, in patients with NSCLC, CRC, PANC, or other solid tumors associated with CEA expression also exhibiting HLA-A*02 LOH

EVEREST-2: A seamless phase 1/2 study of A2B694, a mesothelin (MSLN) logic-gated Tmod CAR T-cell therapy, in patients with non-small cell lung cancer (NSCLC), colorectal cancer (CRC), pancreatic cancer (PANC), ovarian cancer, mesothelioma, or other solid tumors that show MSLN expression and HLA-A*02 LOH

Improving ethnic and racial diversity in biomarker-driven clinical trials: a proof of concept with the BASECAMP-1 master prescreening study of patients with high-risk solid tumors with human leukocyte antigen-A*02 (HLA-A*02) loss of heterozygosity (LOH)

Quantifying clinical actionability of updated tumor profiling reports through electronic health record (EHR)-enabled, on-demand ordering and resulting

TriHealth piloted Tempus Refresh, an on-demand service that updates prior molecular reports with current therapy and clinical trial matches through electronic health record (EHR) integration. TriHealth's pilot demonstrated that 34% of the updated reports listed new FDA-approved therapies, and 78% noted new clinical trials. The service, which integrates into the EHR workflow, provided updated reports with an average turnaround time of 29 hours, enhancing the actionability of tumor profiling in clinical practice.

Changes in non-small cell lung cancer (NSCLC) next-generation sequencing (NGS) rates after electronic health record (EHR) integration using large-scale, multi-institutional real-world data

Tempus and Ochsner, using retrospective Tempus data, evaluated the effect of integrating NGS ordering and resulting into EHRs on the rates of comprehensive NGS testing in non-small cell lung cancer (NSCLC) patients. This analysis of 29 clinical networks showed a 53% increase in NSCLC patient sequencing post-EHR integration, with academic medical centers experiencing a higher increase compared to regional health systems. This suggests that EHR-based workflow improvements may help reduce barriers in biomarker based testing for NSCLC patients.

Real-world (rw) treatment (tx) patterns, sequencing, and outcomes in US patients (pts) with locally advanced or metastatic urothelial cancer (la/mUC) treated with avelumab first-line maintenance (1LM)

Impact of exigent research network’s partnership with the Tempus AI TIME program on the screening and matching of subjects for clinical trials

Exigent Research Network's collaboration with Tempus’ TIME program has significantly improved clinical trial screening and enrollment. Utilizing the AI-powered T-App for patient matching, the network screened over 244,000 patients, resulting in 216 million unique searches and 31,441 matches reviewed by nurses. This led to 71 trial activations and 329 patient consents, with rapid activation times averaging 12.3 days for immediate needs and 33.8 days for prospective activations. The integration of AI technology with a robust trial infrastructure has proven effective in maximizing clinical trial enrollment.

Prognostic impact of BRCA mutation on metastasis-free survival in a localized/locoregional high risk real-world prostate cancer population

Deep learning model on H&E-stained slides predicts whether samples will yield sufficient nucleic acid content for NGS testing